Kos Inhaled Insulin Comparable To Lantus In Phase IIa Trial, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Kos' inhaled insulin formulation demonstrated equivalent efficacy and safety compared to Aventis' injectable basal insulin analog Lantus in a Phase IIa study, the firm reported Aug. 26